Our results support the hypothesized mechanism of inflammation mediating delirium, with higher levels of IL-1β, IL-6 and TNF-α being significantly related to higher levels of delirium severity—supporting the possible use of anti-inflammatory agents as novel therapies to target this potentially reversible condition. This evidence concerns the gene TNF and delirium.